{"downloaded": true, "htmlmade": false, "full": {"id": "29895668", "source": "MED", "pmid": "29895668", "pmcid": "PMC6107882", "fullTextIdList": {"fullTextId": "PMC6107882"}, "doi": "10.1182/blood-2018-01-828343", "title": "Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.", "authorString": "Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, Bot A.", "authorList": {"author": [{"fullName": "Rossi J", "firstName": "John", "lastName": "Rossi", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Kite, a Gilead Company, Santa Monica, CA."}}}, {"fullName": "Paczkowski P", "firstName": "Patrick", "lastName": "Paczkowski", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Shen YW", "firstName": "Yueh-Wei", "lastName": "Shen", "initials": "YW", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Kite, a Gilead Company, Santa Monica, CA."}}}, {"fullName": "Morse K", "firstName": "Kevin", "lastName": "Morse", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Flynn B", "firstName": "Brianna", "lastName": "Flynn", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Kaiser A", "firstName": "Alaina", "lastName": "Kaiser", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Ng C", "firstName": "Colin", "lastName": "Ng", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Gallatin K", "firstName": "Kyle", "lastName": "Gallatin", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Cain T", "firstName": "Tom", "lastName": "Cain", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Fan R", "firstName": "Rong", "lastName": "Fan", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biomedical Engineering, Yale School of Engineering and Applied Science, Yale University, New Haven, CT."}}}, {"fullName": "Mackay S", "firstName": "Sean", "lastName": "Mackay", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Heath JR", "firstName": "James R", "lastName": "Heath", "initials": "JR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Divison of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA; and."}}}, {"fullName": "Rosenberg SA", "firstName": "Steven A", "lastName": "Rosenberg", "initials": "SA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Surgery Branch, and."}}}, {"fullName": "Kochenderfer JN", "firstName": "James N", "lastName": "Kochenderfer", "initials": "JN", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD."}}}, {"fullName": "Zhou J", "firstName": "Jing", "lastName": "Zhou", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "IsoPlexis, Branford, CT."}}}, {"fullName": "Bot A", "firstName": "Adrian", "lastName": "Bot", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Kite, a Gilead Company, Santa Monica, CA."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "8", "volume": "132", "journalIssueId": "2719120", "dateOfPublication": "2018 Aug", "monthOfPublication": "8", "yearOfPublication": "2018", "printPublicationDate": "2018-08-01", "journal": {"title": "Blood", "ISOAbbreviation": "Blood", "medlineAbbreviation": "Blood", "NLMid": "7603509", "ISSN": "0006-4971", "ESSN": "1528-0020"}}, "pubYear": "2018", "pageInfo": "804-814", "abstractText": "After treatment with chimeric antigen receptor (CAR) T cells, interleukin-15 (IL-15) elevation and CAR T-cell expansion are associated with non-Hodgkin lymphoma (NHL) outcomes. However, the association of preinfusion CAR product T-cell functionality with clinical outcomes has not been reported. A single-cell analysis of the preinfusion CD19 CAR product from patients with NHL demonstrated that CAR products contain polyfunctional T-cell subsets capable of deploying multiple immune programs represented by cytokines and chemokines, including interferon-\u03b3, IL-17A, IL-8, and macrophage inflammatory protein 1\u03b1. A prespecified T-cell polyfunctionality strength index (PSI) applied to preinfusion CAR product was significantly associated with clinical response, and PSI combined with CAR T-cell expansion or pretreatment serum IL-15 levels conferred additional significance. Within the total product cell population, associations with clinical outcomes were greater with polyfunctional CD4<sup>+</sup> T cells compared with CD8<sup>+</sup> cells. Grade \u22653 cytokine release syndrome was associated with polyfunctional T cells, and both grade \u22653 neurologic toxicity and antitumor efficacy were associated with polyfunctional IL-17A-producing T cells. The findings in this exploratory study show that a preinfusion CAR product T-cell subset with a definable polyfunctional profile has a major association with clinical outcomes of CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT00924326.", "affiliation": "Kite, a Gilead Company, Santa Monica, CA.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial", "research-article", "Journal Article"]}, "grantsList": {"grant": {"grantId": "R44 CA210841", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "Y", "descriptorName": "CD4-Positive T-Lymphocytes", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TR", "qualifierName": "transplantation", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "CD8-Positive T-Lymphocytes", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TR", "qualifierName": "transplantation", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "K562 Cells"}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "Y", "descriptorName": "Lymphoma, Non-Hodgkin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Receptors, Antigen, T-Cell", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Cytokines", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "Y", "descriptorName": "Adoptive Transfer"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Receptors, Chimeric Antigen", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}]}, "chemicalList": {"chemical": [{"name": "Receptors, Antigen, T-Cell", "registryNumber": "0"}, {"name": "Cytokines", "registryNumber": "0"}, {"name": "Receptors, Chimeric Antigen", "registryNumber": "0"}, {"name": "tisagenlecleucel", "registryNumber": "Q6C9WHR03O"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2018-01-828343"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6107882"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2018-01-828343"}]}, "commentCorrectionList": {"commentCorrection": {"id": "30139827", "source": "MED", "reference": "Blood. 2018 Aug 23;132(8):769-770", "type": "Comment in", "orderIn": "1"}}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "N", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "49", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-07-15", "dateOfCreation": "2018-06-14", "firstIndexDate": "2018-06-14", "fullTextReceivedDate": "2020-07-12", "dateOfRevision": "2021-04-15", "electronicPublicationDate": "2018-06-12", "firstPublicationDate": "2018-06-12", "embargoDate": "2019-08-23"}, "abstract": "After treatment with chimeric antigen receptor (CAR) T cells, interleukin-15 (IL-15) elevation and CAR T-cell expansion are associated with non-Hodgkin lymphoma (NHL) outcomes. However, the association of preinfusion CAR product T-cell functionality with clinical outcomes has not been reported. A single-cell analysis of the preinfusion CD19 CAR product from patients with NHL demonstrated that CAR products contain polyfunctional T-cell subsets capable of deploying multiple immune programs represented by cytokines and chemokines, including interferon-\u03b3, IL-17A, IL-8, and macrophage inflammatory protein 1\u03b1. A prespecified T-cell polyfunctionality strength index (PSI) applied to preinfusion CAR product was significantly associated with clinical response, and PSI combined with CAR T-cell expansion or pretreatment serum IL-15 levels conferred additional significance. Within the total product cell population, associations with clinical outcomes were greater with polyfunctional CD4<sup>+</sup> T cells compared with CD8<sup>+</sup> cells. Grade \u22653 cytokine release syndrome was associated with polyfunctional T cells, and both grade \u22653 neurologic toxicity and antitumor efficacy were associated with polyfunctional IL-17A-producing T cells. The findings in this exploratory study show that a preinfusion CAR product T-cell subset with a definable polyfunctional profile has a major association with clinical outcomes of CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT00924326.", "journaltitle": "Blood", "authorinfo": ["Rossi J", "Paczkowski P", "Shen YW", "Morse K", "Flynn B", "Kaiser A", "Ng C", "Gallatin K", "Cain T", "Fan R", "Mackay S", "Heath JR", "Rosenberg SA", "Kochenderfer JN", "Zhou J", "Bot A"], "title": "Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL."}